Innovo Mimetics Ltd (IML)
Sector: Biotechnology - Therapeutics
Medical Field: Oncology
Technological Field: Animal models, Tumor Xenografts, anti-cancer therapy
Year Established: 2011
Innovo Mimetics Ltd (IML) offers an alternative to cancer research in sentient animals (mice) – growing cancer in chicken eggs.
The company was founded by Prof. Ron Goldstein (CSO) of Bar Ilan University and Jonathan Goldstein (CEO), to calibrate novel in vivo models for cancer research and for clinical applications.
Preclinical and clinical studies in cancer research are based on tumor-bearing, immune-deficient mice that are expensive to maintain and can take several months to yield results. There are currently no in vivo alternatives to cancer therapy studies in the mouse.
Thanks to OCTIPS, an EU-funded FP7 consortium project, IML has developed an ovarian cancer model in the egg, whereby chemotherapy or targeted drugs can be rapidly assessed for anti-cancer activity, on both cell lines and patient primary cancer cells.
Based in the JBP-Minrav Building, Ein Karem, we employ a top quality in-house research team comprised of post-docs, PhDs and researchers who are dedicated to providing clients with a faster, cost-effective alternative to current in vivo models for studying anti-cancer drug activity.